Ironwood Pharmaceuticals Inc (IRWD, Financial) is a specialty and generic drug manufacturing company, focusing on advancing innovative product opportunities in areas of large unmet need. With an outstanding share count of 156.03 million, the company has seen significant institutional and insider ownership, which provides a glimpse into the confidence key players have in the firm's future.
As of the latest data, institutional ownership stands at 98.77 million shares, constituting 63.3% of the total shares. Meanwhile, insiders hold 9.27 million shares, accounting for 5.94% of the total share count. The recent performance of Ironwood Pharmaceuticals Inc's stock, which experienced a decline of about 5.28% over the past week, has sparked keen interest in the company's ownership trends.
Institutional Ownership and Key Players
The company's institutional ownership history reveals the levels of trust and confidence that major players have in the company's future. As of 2023-08-31, the institutional ownership level is 63.3%, down from 66.17% as of 2023-05-31 and 92.78% from a year ago.
Among the most significant stakeholders, the top fund managers owning chunks of Ironwood Pharmaceuticals Inc's stock are HOTCHKIS & WILEY (Trades, Portfolio), First Eagle Investment (Trades, Portfolio), and Jefferies Group (Trades, Portfolio), with 0.64%, 0.38%, and 0.21% of shares outstanding respectively.
Delving into Earnings: Past and Future
Over the past three years, Ironwood Pharmaceuticals Inc's Ebitda growth averaged 29.4% per year, better than 75.99% of 887 companies in the Drug Manufacturers industry. Looking forward, the estimated earnings growth for the company is 0% per year, lower than the earnings growth of 36.2% during the past three years.
Insider Ownership and Activities
Insider ownership offers insights into the convictions of the company's board directors and C-level employees. Ironwood Pharmaceuticals Inc's insider ownership is approximately 5.94% as of 2023-08-31, compared to insider ownership of 5.77% from a year ago, reflecting the increased faith of those intimately familiar with the company's operations.
In the ever-evolving realm of stocks, understanding the nuances of ownership and earnings is critical. Ironwood Pharmaceuticals Inc's recent dip is a case study in how major players react to market shifts, and their movements offer crucial insights for potential investors. As always, a holistic view, combining both past performance and future projections, remains key to sound investment decisions.
